

SINGLE PRE- CONTRACTUAL FORM (MUP) FOR INSURANCE INVESTMENT PRODUCTS

ITALY

ANNEX 4 - SINGLE PRE-CONTRACTUAL FORM (MUP) FOR INSURANCE INVESTMENT PRODUCTS

The distributor is required to deliver/send this Form to the policyholder before the insurance proposal or contract is signed. The document may be provided in non-paper form if appropriate to the distribution methods of the insurance investment product and if the policyholder agrees (Article 120-quater of the Private Insurance Code).

SECTION I - GENERAL INFORMATION ON THE DISTRIBUTOR WHO COMES INTO CONTACT WITH THE POLICYHOLDER

Identification of the company selling the insurance product directly (without using intermediaries):

- a) Name and status of insurance company: **Utmost Luxembourg S.A.** is a company incorporated under the laws of the Grand Duchy of Luxembourg and authorised by the Commissariat aux Assurances ("CAA"), the Luxembourg supervisory authority, to carry out life insurance activities in the Grand Duchy of Luxembourg under registration number R.C.S. Luxembourg B37604. In accordance with Directive 2009/138/EC of the European Parliament and of the Council of 25 November 2009 on the taking-up and pursuit of the business of Insurance and Reinsurance, it may carry out such activities in Italy on the basis of the freedom to provide services.
- b) Registration number in the Register of Companies kept by the Insurance Supervisory Authority (IVASS), available on the website www.ivass.it: Il. 00148
- c) Registered office: 4, rue Lou Hemmer, L-1748 Luxembourg, Grand Duchy of Luxembourg
- d) Telephone number: +352 34 61 91
Certified email address: utmostluxembourg@legalmail.it
- e) Website: www.utmostinternational.com

SECTION II - INFORMATION ON THE DISTRIBUTION MODEL

Pursuant to Article 109, paragraph 1-bis of Legislative Decree No. 209 of 7 September 2005, the company operates directly as a distributor through its employees and/or via remote communication techniques.

The company's distribution model provides, alternatively, for the possibility of using external intermediaries for the promotion and placement of its products.

SECTION III - INFORMATION RELATING TO POTENTIAL CONFLICTS OF INTEREST

The company does not hold any direct or indirect shareholding equal to or greater than 10% of the share capital or voting rights of insurance intermediaries.

SECTION IV - INFORMATION ON DISTRIBUTION AND CONSULTANCY ACTIVITIES

- a) The company distributes its insurance investment products with a personalised recommendation, in accordance with Article 119-ter, paragraph 3 of the Private Insurance Code, explaining why the recommended product is considered suitable for the customer's needs, objectives and profile.
- During the pre-contractual phase, the company provides advice based on the customer's need and demands, their financial situation and their knowledge and experience with insurance investment products. Based on this information, the company performs a suitability assessment, determining the policyholder's risk tolerance and ability to bear losses. The company provides a personalized recommendation based on the outcome of that assessment.
- b) The company provides this advice free of charge and on a mandatory basis, pursuant to Article 121-septies of the Private Insurance Code, as it has assessed its products as complex products.
- c) The company does not carry out a periodic assessment of the suitability of the product. However, if new information is provided during the life of the policy, the company may carry out a new suitability assessment..
- d) For specific information on the product, such as its characteristics, duration, costs and coverage limits, and any other information useful to enable the policyholder to make an informed decision, please refer to the document containing key information on the insurance investment product referred to in Regulation (EU) No 1286/2014 of 26 November 2014 (KID), including the SID, and the additional pre-contractual information document referred to in Article 185 of the Private Insurance Code (Additional DIP IBIP).
- e) For information on the proposed investment strategies, including appropriate guidance and warnings on the risks associated with the proposed insurance investment products or certain proposed investment strategies, please refer to the document containing key information on the insurance investment product referred to in Regulation (EU) No. 1286/2014 of 26 November 2014 (KID), including the SID, the additional pre-contractual information document referred to in Article 185 of the Private Insurance Code (Additional DIP IBIP), as well as any additional information and contractual documentation prepared by the Insurer.
- f) The company has implemented internal procedures to identify any conflicts of interest that may arise during the distribution phase between the company, its employees and potential customers, as well as organisational safeguards to prevent such conflicts from adversely affecting the interests of the contracting parties.

In relation to the promotion, intermediation and conclusion of the policy, the Insurer is not in a situation of conflict of interest. However, it could find itself in such a situation in the event of investment and divestment transactions and/or (ii) related activities, such as deposits and/or management. These transactions and/or activities could arise when the issuer of the eligible assets, the relevant managers or the custodian bank have business or corporate relationships with the Insurer. In any case, even in the presence of an unavoidable conflict of interest, the Insurer must operate in such a way as to avoid prejudicing the interests of the Policyholder. The Insurer has defined a policy to identify, prevent and manage conflicts of interest. This policy is particularly aimed at:

- › to identify situations of potential conflict of interest;
- › to prevent and manage potential conflicts of interest;
- › to inform the Policyholder of potential conflicts of interest that could harm its interests;
- › to record conflicts of interest.

The Policyholder may request and obtain from the Insurer further information on the policy concerning conflicts of interest and obtain a copy of the document containing it.

SECTION V - INFORMATION ON REMUNERATION AND INCENTIVES

- a) Employees of the company who distribute insurance investment products do not receive any compensation for the distribution of insurance investment products.
- b) There are no costs, charges or incentives associated with the distribution of insurance investment products carried out pursuant to Article 109, paragraph 1-bis of Legislative Decree No. 209 of 7 September 2005, through its employees and/or through the use of remote communication techniques.
- c) No additional compensation is provided for any update of the suitability assessment.

SECTION VI - INFORMATION ON THE PAYMENT OF PREMIUMS

The Initial Single Premium and any Additional Premiums may be paid by the Policyholder using the following methods, which may be selected by the Policyholder in the Application Form:

- a. bank transfer to the account details provided by the Insurer;

SINGLE PRE-CONTRACTUAL FORM (MUP) FOR INSURANCE INVESTMENT PRODUCTS

- b. payment in kind by transferring Eligible Assets for a corresponding amount to the account details provided by the Insurer;
- c. combination of bank transfer and transfer of Eligible Assets.

SECTION VII - INFORMATION ON POLICYHOLDER PROTECTION TOOLS

Information on the tools available to protect the Policyholder is provided via the additional IBIP DIP.

SECTION VIII - INFORMATION ON THE ONCOLOGICAL OBLIVION RIGHT

The Policyholder may exercise the right to be forgotten in oncology, as outlined in Article 2 of Law No. 193 of 7 December 2023, provided that they meet specific criteria. Firstly, they must have suffered from an oncological disease for which active treatment has been concluded, without recurrence, for more than ten years prior to the date of the request. Please note that this period is reduced by half if the disease began before the age of twenty-one.

In such cases, information relating to previous oncological diseases cannot be requested or acquired. Please be advised that the Insurer does not utilise any information available to it for the purpose of determining or modifying the contractual conditions. The Insurer is unable to apply additional limits, costs, or charges, nor apply different treatments than those provided for all contracting parties.

The implementation procedures, including the management of any health information already provided and its deletion following the submission of appropriate certification, are governed by Articles 56-bis, 56-ter, and 68-bis of IVASS Regulation No. 40/2018.

For a comprehensive overview of the conditions, effects, and operating procedures for exercising this right, please refer to the Additional Instructional Plan (DIP).

The Policyholder should be aware that any contractual clauses entered into in breach of the provisions of Article 2, paragraphs 1 to 5 of Law No. 192 of 7 December 2023 are null and void. However, this will not affect the effectiveness and validity of the contract. Nullity operates solely in the interest of the policyholder or the insured, and may be declared ex officio at any stage and level of the proceedings.

A WEALTH *of* DIFFERENCE

www.utmostinternational.com

Utmost Luxembourg S.A. is registered with R.C.S. under number B37604 and regulated by the Commissariat aux Assurances (CAA)
Registered office address: 4, rue Lou Hemmer, L-1748 Luxembourg, Grand-Duché de Luxembourg
Utmost Wealth Solutions is registered in Luxembourg as a business name of Utmost Luxembourg S.A.